TheraRadar
Data updated: Mar 29, 2026

METHYLNALTREXONE BROMIDE

METHYLNALTREXONE BROMIDE
Approved 2024-08-26
Jump to: Indications Approvals Trials Competitors Safety Patents
2
Indications
--
Phase 3 Trials
1
Years on Market

Details

Status
Discontinued
First Approved
2024-08-26
Routes
SUBCUTANEOUS
Dosage Forms
SOLUTION

Companies

Viatris US GENERICS, STERILES Teva
Active Ingredient: METHYLNALTREXONE BROMIDE

METHYLNALTREXONE BROMIDE Approval History

Loading approval history...

What METHYLNALTREXONE BROMIDE Treats

2 FDA approvals

Originally approved for its first indication in 2024 . Covers 2 distinct patient populations.

  • Other (2)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

METHYLNALTREXONE BROMIDE FDA Label Details

Pro

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

FDA Approval: ANDA208592 → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.